检索结果-南通市图书馆

Immune checkpoint inhibitor resistance in soft tissue sarcoma

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

cancer Drug Resistance 2022年第2期5卷 328-338页

作者： Vanessa Eulo Brian A.Van Tine division of Medical oncology University of Alabama at BirminghamBirminghamAL35233USA. division of Medical oncology Washington University in St.LouisSt.LouisMO63110USA. division of Pediatric hematology/oncology Washington University in St.LouisSt.LouisMO63110USA. Siteman cancer center St.LouisMO 63110USA.

The emergence of immunotherapy as a cancer therapy has dramatically changed the treatment paradigm of systemic cancer *** have been several trials evaluating immune checkpoint blockade(ICI)in soft tissue *** there is generally a limited response in sarcoma,a subset of patients has durable responses to *** is attributable to a variety of factors including histologic subtype,tumor-infiltrating lymphocytes,and the tumor microenvironment among *** is ongoing translational and clinical research evaluating ICI resistance in sarcoma and identifying therapeutic strategies to overcome this ***,we provide a review of the current data,proposed mechanisms of resistance,and potential approaches to overcome this resistance.

关键词： Sarcoma soft tissue sarcoma checkpoint inhibitor immunotherapy resistance

Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

cancer Drug Resistance 2023年第4期6卷 858-873页

作者： Patrick L.Sweeney Yash Suri Arnab Basu Vadim S.Koshkin Arpita Desai Deming Department of Medicine Tulane University School of MedicineNew OrleansLA 70112USA university of Arizona College of Medicine TucsonAZ 85724USA division of hematology and oncology Department of MedicineUniversity of Alabama at Birmingham Heersink School of MedicineBirminghamAL35233USA division of hematology and oncology Department of MedicineUniversity of California at San Francisco School of MedicineSanFranciscoCA94143USA

Renal cell carcinoma(RCC),the most prevalent type of kidney cancer,is a significant cause of cancer morbidity and mortality *** tyrosine kinase inhibitors(TKls),in combination with immune checkpoint inhibitors(ICls),are among the first-line treatment options for patients with advanced *** therapies target the vascular endothelial growth factor receptor(VEGFR)tyrosine kinase pathway and other kinases crucial to cancer proliferation,survival,and *** have yielded substantial improvements in progression-free survival(PFS)and overall survival(OS)for patients with advanced ***,nearly all patients eventually progress on these drugs as resistance *** review provides an overview of TKl resistance in RCC and explores different mechanisms of resistance,including upregulation of alternative proangiogenic pathways,epithelial-mesenchymal transition(EMT),decreased intracellular drug concentrations due to efflux pumps and lysosomal sequestration,alterations in the tumor microenvironment including bone marrow-derived cells(BMDCs)and tumor-associated fibroblasts(TAFs),and genetic factors such as single nucleotide polymorphisms(SNPs).A comprehensive understanding of these mechanisms opens the door to the development of innovative therapeutic approaches that can effectively overcome TKl resistance,thereby improving outcomes for patients with advanced RCC.

关键词： Antiangiogenic tyrosine kinase inhibitors renal cell carcinoma acquired resistance sunitinib tumor microenvironment immune checkpoint inhibitors

A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Science China(Life Sciences) 2022年第11期65卷 2205-2217页

作者： Chang Gong Ziliang Cheng Yaping Yang Jun Shen Yingying Zhu Li Ling Wanyi Lin Zhigang Yu Zhihua Li Weige Tan Chushan Zheng Wenbo Zheng Jiajie Zhong Xiang Zhang Yunjie Zeng Qiang Liu RStephanie Huang Andrzej LKomorowski Eddy SYang François Bertucci Francesco Ricci Armando Orlandi Gianluca Franceschini Kazuaki Takabe Suzanne Klimberg Naohiro Ishii Angela Toss Mona PTan Mathew A Cherian Erwei Song Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Guangdong-Hong Kong Joint Laboratory for RNA MedicineBreast Tumor CenterSun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhou 510120China Department of Radiology Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhou 510120China Clinical Research Design division Clinical Research CenterSun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhou 510120China Department of Medical Statistics School of Public HealthSun Yat-sen UniversityGuangzhou 510080China Department of Breast Surgery the Second Affiliated HospitalShandong UniversityJinan 250033China Department of Breast Surgery Key Laboratory of Breast DiseasesThird Hospital of NanchangNanchang 330009China Department of Breast Surgery the First Affiliated HospitalGuangzhou Medical UniversityGuangzhou 510120China Department of Pathology Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhou 510120China Department of Experimental and Clinical Pharmacology University of MinnesotaMinneapolisMN 55455USA Department of Surgery College of MedicineUniversity of RzeszówRzeszów 35-959Poland Department of Radiation oncology O’Neal Comprehensive Cancer CenterUniversity of Alabama at Birmingham School of MedicineBirminghamALUSA Laboratoty of Predictive oncology Institut Paoli-CalmettesCentre de Recherche en Cancérologie de MarseilleINSERM UMR1068CNRS UMR725MarseilleFrance Department of Drug Development and Innovation(D3i) Institut CurieParis 75005France comprehensive cancer center UOC di Oncologia MedicaFondazione Policlinico Universitario A.Gemelli IRCCSRome 00168Italy Multidisciplinary Breast Unit Fondazione Policlinico Universitario Agostino Gemelli IRCCSUniversitàCattolica del Sacro CuoreRome 00168Italy Breast Surgery Department of Surgical OncologyRoswell Park Comprehensive Cancer CenterBuffaloNYUSA Department of Surgery MD Anderson Cancer CenterHoustonTX 77030USA Department of Plastic and Reconstructive Surgery

Patients with hormone receptor(HR)-positive tumors breast cancer usually experience a relatively low pathological complete response(p CR)to neoadjuvant chemotherapy(NAC).Here,we derived a 10-micro RNA risk score(10-mi RNA RS)-based model with better performance in the prediction of p CR and validated its relation with the disease-free survival(DFS)in 755 HRpositive breast cancer patients(273,265,and 217 in the training,internal,and external validation sets,respectively).This model,presented as a nomogram,included four parameters:the 10-mi RNA RS found in our previous study,progesterone receptor(PR),human epidermal growth factor receptor 2(HER2)status,and volume transfer constant(K).Favorable calibration and discrimination of 10-mi RNA RS-based model with areas under the curve(AUC)of 0.865,0.811,and 0.804 were shown in the training,internal,and external validation sets,*** who have higher nomogram score(>92.2)with NAC treatment would have longer DFS(hazard ratio=0.57;95%CI:0.39–0.83;P=0.004).In summary,our data showed the 10-mi RNA RS-based model could precisely identify more patients who can attain p CR to NAC,which may help clinicians formulate the personalized initial treatment strategy and consequently achieves better clinical prognosis for patients with HRpositive breast cancer.

关键词： hormone receptor-positive breast cancer micro RNA signature neoadjuvant chemotherapy dynamic contrast-enhanced magnetic resonance imaging nomogram

A Retrospective Evaluation of Chemotherapy Regimens in Unselected Patients with Metastatic Non-Small Cell Lung cancer

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Journal of cancer Therapy 2018年第3期9卷 314-322页

作者： Ahmed Ashour Badawy Abbas Omar Waleed Arafat Gehan Khedr Sejong Bae Stefan Grant Clinical oncology and Nuclear Medicine Department University of Alexandria Faculty of Medicine Alexandria Egypt Preventive Medicine division University of Alabama at Birmingham Birmingham AL USA hematology oncology division Wake Forest University Comprehensive Cancer Center Winston Salem NC USA

Background: Randomized clinical trials have demonstrated the benefits of chemotherapy in carefully selected non-small cell lung cancer (NSCLC) patients. How generalizable these results are to other NSCLC patients is unresolved. Methods: The outcomes of patients treated with standard chemotherapy regimens (paclitaxel / carboplatin;gemcitabine / carboplatin;pemetrexed / carboplatin;paclitaxel / carboplatin / bevacizumab) off study as first line therapy between 2002 and 2012 at our institution were compared to the reported results of trials supporting the FDA approval of these drugs and/or regimens. Results: In our population, 38.1% of the patients had hypertension, 11.9% of the patients were diabetic, 23.7% had chronic obstructive pulmonary disease (COPD), 11.9% had coronary artery disease (CAD) and 2.1% had renal or liver disease. Notably, the presence of a single or multiple comorbidities was associated with low overall survival compared to matched patients with no comorbidities (p = 0.007). Conclusion: The presence of single or multiple comorbidities is associated with inferior overall survival compared to matched groups without such pre-existing conditions.

关键词： NSCLC-Lung cancer Chemotherapy-Comorbidities

Drugging SUMOylation for neuroprotection and oncotherapy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Neural Regeneration Research 2018年第3期13卷 415-416页

作者： Joshua D. Bernstock Daniel G. Ye Yang-ja Lee Florian Gessler Gregory K. Friedman Wei Zheng John M. Hallenbeck Stroke Branch National Institute of Neurological Disorders and Stroke National institutes of Health (NINDS/NIH) Bethesda MD USA Department of Clinical Neurosciences - division of Stem Cell Neurobiology Wellcome Trust-Medical Research Council Stem Cell Institute and NIHR Biomedical Research Centre University of Cambridge UK Department of Pediatrics Division of Pediatric Hematology and Oncology University of Alabama at Birmingham Birmingham AL USA National center for Advancing Translational Sciences National Institutes of Health (NCATS/NIH) Bethesda MD USA

Recently there have been exciting research advances in neuroprotective therapies for ischemic stroke. In the past, the search for neu- roprotective agents has been fraught with failure at the clinical trials stage due to numerous factors, including subject heterogeneity and improper therapeutic windows （Tymianski, 2017）. Moreover, it is becoming clearer that the complex and evolving pathobiology of stroke requires multimodal therapeutic approaches capable of modulating the numerous axes that contribute to ischemia/reperfusion damage, rather than targeting a single axis （Bernstock et al., 2018a）. With the success of recent endovascular thrombectomy （EVT） trials, it has been suggested that clinical trials of EVT with adjunct neuroprotection can overcome past difficulties and maximize the effect size by using imaging to reduce patient heterogeneity （i. e., selecting those with large vessel occlusions, small ischemic cores, and good collateral circulation）, restoring perfusion using better EVT devices, and enrolling patients in the correct therapeutic window （i.e., when they still have salvageable brain tissue）（Tymianski, 2017）. Considering the opportunity that this represents for new, better clinical trials of neuroprotective agents, the search is on for high-potential compounds that may be investigated in these future studies.

关键词： Drugging SUMOylation for neuroprotection and oncotherapy OGD

Leukemia:研究鉴定出与34种AML白血病亚群相关联的基因突变

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

现代生物医学进展 2017年第15期17卷 I0002-I0003页

作者： A-K Eisfeld K Mrózek J Kohlschmidt D Nicolet S Orwick C J Walker K W Kroll J S Blachly A J Carroll J E Kolitz B L Powell E S Wang R M Stone A de la Chapelle J C Byrd C D Bloomfield The Ohio State university comprehensive cancer center Columbus OH USA Alliance Statistics and Data center Mayo Clinic Rochester MN USA division of hematology Department of Internal Medicine The Ohio State University Comprehensive Cancer Center Columbus OH USA Department of Genetics University of Alabama at Birmingham Birmingham AL USA Monter cancer center Hofstra North Shore-Long Island Jewish School of Medicine Lake Success NY USA comprehensive cancer center of Wake Forest university Winston-Salem NC USA Department of Medicine Roswell Park Cancer Institute Buffalo NY USA Department of Medical oncology Dana-Farber/Partners CancerCare Boston MA USA

针对成年急性髓细胞白血病（acute myeloid leukemia，AML）患者的一项新的大型研究将80种癌症相关基因突变与5种AML亚型相关联。这5种AML亚型可通过特异性的染色体异常加以确定。在未来，这些发现可能有助指导基因突变测试和治疗决策。

关键词：基因突变 AML 白血病关联亚群鉴定染色体异常髓细胞

The SUPER reporting guideline suggested for reporting of surgical technique

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatobiliary Surgery and Nutrition 2023年第4期12卷 534-544,I0024-I0026页

作者： Kaiping Zhang Yanfang Ma Jinlin Wu Qianling Shi Leandro Cardoso Barchi Marco Scarci Rene Horsleben Petersen Calvin S.H.Ng Steven Hochwald Ryuichi Waseda Fabio Davoli Robert Fruscio Giovanni Battista Levi Sandri Michel Gonzalez Benjamin Wei Guillaume Piessen Jianfei Shen Xianzhuo Zhang Panpan Jiao Yulong He Nuria M.Novoa Benedetta Bedetti Sebastien Gilbert Alan D.L.Sihoe Alper Toker Alfonso Fiorelli Marcelo F.Jimenez Toni Lerut Aung Y.Oo Grace S.Li Xueqin Tang Yawen Lu Hussein Elkhayat Tomaz Stupnik Tanel Laisaar Firas Abu Akar Diego Gonzalez-Rivas Zhanhao Su Bin Qiu Stephen D.Wang Yaolong Chen Shugeng Gao Editorial Office AME Publishing CompanyHong KongChina School of Chinese Medicine Hong Kong Baptist UniversityHong KongChina Department of Cardiovascular Surgery Guangdong Provincial People’s HospitalGuangdong Academy of Medical SciencesGuangzhouChina Evidence-based Medicine center School of Basic Medical SciencesLanzhou UniversityLanzhouChina Lanzhou university Institute of Health Data Science LanzhouChina Digestive Surgery division Department of GastroenterologyUniversity of Sao Paulo School of MedicineSão PauloBrazil Department of Cardiothoracic Surgery Imperial College Healthcare NHS TrustLondonUK Department of Cardiothoracic Surgery University Hospital of CopenhagenRigshospitaletCopenhagenDenmark The Chinese university of Hong Kong Prince of Wales HospitalShatinNew TerritoriesHong KongChina Department of Surgical oncology Roswell Park Cancer InstituteBuffaloNYUSA Department of General Thoracic Breast and Pediatric SurgeryFukuoka UniversityFukuokaJapan Department of Thoracic Surgery AUSL RomagnaS.Maria delle Croci Teaching HospitalRavennaItaly Clinic of Obstetrics and Gynecology University of Milan-BicoccaSan Gerardo HospitalMonzaItaly division of General Surgery and Liver Transplantation S.Camillo HospitalRomeItaly Service of Thoracic Surgery Lausanne University Hospital(CHUV)LausanneSwitzerland division of Cardiothoracic Surgery Department of SurgeryUniversity of Alabama BirminghamBirminghamALUSA university of Lille CNRSInsermCHU LilleUMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to TherapiesLilleFrance Department of Cardiothoracic Surgery Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical UniversityLinhaiChina The First School of Clinical Medicine Lanzhou UniversityLanzhouChina Thoracic Surgery Service University Hospital of SalamancaBiomedical Institute of SalamancaSalamancaSpain Department of Thoracic Surgery Helios Clinic Bonn/Rhein SiegBonnGermany division of Thoracic Surgery Department of SurgeryThe Ottawa

Background:Existing reporting guidelines pay insufficient attention to the detail and comprehensiveness reporting of surgical *** Surgical techniqUe rePorting chEcklist and standaRds(SUPER)aims to address this gap by defining reporting standards for surgical *** SUPER guideline intends to apply to articles that encompass surgical technique in any study design,surgical discipline,and stage of surgical ***:Following the EQUATOR(Enhancing the QUAlity and Transparency Of health Research)Network approach,16 surgeons,journal editors,and methodologists reviewed existing reporting guidelines relating to surgical technique,reviewed papers from 15 top journals,and brainstormed to draft initial items for the *** initial items were revised through a three-round Delphi survey from 21 multidisciplinary Delphi panel experts from 13 countries and *** final SUPER items were formed after an online consensus meeting to resolve disagreements and a three-round wording refinement by all 16 SUPER working group members and five SUPER ***:The SUPER reporting guideline includes 22 items that are considered essential for good and informative surgical technique *** items are divided into six sections:background,rationale,and objectives(items 1 to 5);preoperative preparations and requirements(items 6 to 9);surgical technique details(items 10 to 15);postoperative considerations and tasks(items 16 to 19);summary and prospect(items 20 and 21);and other information(item 22).Conclusions:The SUPER reporting guideline has the potential to guide detailed,comprehensive,and transparent surgical technique reporting for *** may also assist journal editors,peer reviewers,systematic reviewers,and guideline developers in the evaluation of surgical technique papers and help practitioners to better understand and reproduce surgical technique.

关键词： Surgical technique surgical innovation reporting guideline reporting checklist Surgical techniqUe rePorting chEcklist and standaRds(SUPER)

Early Outpatient Treatment for Covid-19 with Convalescent Plasma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

四川生理科学杂志 2022年第2期44卷 366-366页

作者： David J Sullivan From the Department of Medicine Division of Infectious Diseases (K.A.G. S.S.) the Department of Pathology (E.M.B. C.E.M. A.A.R.T.) the Department of Neurology Brain Injury Outcomes Division (A.Y. K.L. N.A.M. A.L.G. N.K. D.F.H.) the Department of Ophthalmology (D.A.J.) the Welch Center for Prevention Epidemiology and Clinical Research (L.J.A.) and the Institute for Clinical and Translational Research (D.E.F.) Johns Hopkins School of Medicine and the Departments of Molecular Microbiology and Immunology (D.J.S. A.S. A.P. S.L.K. A.C.) International Health (L.L.H. C.G.S.) and Epidemiology (B.L. D.M.S. S.E. S.N.B.) Johns Hopkins Bloomberg School of Public Health Johns Hopkins University Baltimore the Division of Intramural Research National Institute of Allergy and Infectious Diseases Bethesda (O.L.) and Luminis Health Annapolis (B.R.M.) - all in Maryland the Department of Medicine Division of Hematology and Oncology MedStar Washington Hospital Center (A.G.S.) and the Department of Medicine Division of Infectious Diseases Georgetown University Medical Center (S.G.K.) - both in Washington DC the division of Allergy and Immunology Department of Medicine (G.S.M.) and the Department of Pathology (T.J.G.) NorthShore University Health System Evanston IL the Department of Medicine Section of Infectious Diseases Baylor College of Medicine (Y.F.) the Department of Medicine Division of Pulmonary and Critical Care Medicine University of Texas Health Science Center (B.P.) Houston and The Next Practices Group Austin (E.C.F.) - all in Texas the Department of Medicine Division of Infectious Diseases University of Alabama at Birmingham Birmingham (S.L.H.) the Department of Emergency Medicine Rhode Island Hospital Brown University Providence RI (A.C.L.) the Department of Medicine Division of Infectious Diseases University of Utah School of Medicine Salt Lake City (E.S.S.) the Department of Medicine Division of Infectious Diseases University of Miami Miller School of Med

Background:Polyclonal convalescent plasma may be obtained from donors who have recovered from coronavirus disease 2019(Covid-19).The efficacy of this plasma in preventing serious complications in outpatients with rece... 详细信息

关键词： Plasma uncertain recovered

Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

四川生理科学杂志 2021年第10期43卷 1802-1802页

作者： Julie Kanter From the university of alabama birmingham Birmingham (J.K.) UCSF Benioff Children's Hospital Oakland CA (M.C.W.) Aflac cancer and Blood Disorders center Department of Pediatrics Children's Healthcare of Atlanta Emory University Atlanta (L.K.) the division of hematology-oncology Columbia Center for Translational Immunology Columbia University Medical Center New York (M.Y.M.) the Division of Pediatric Hematology Oncology and Cellular Therapy Cohen Children's Medical Center New Hyde Park (B.A.) and Zucker School of Medicine at Hofstra-Northwell Hempstead (B.A.) - all in New York the division of hematology Children's Hospital of Philadelphia and the Department of Pediatrics University of Pennsylvania Perelman School of Medicine - both in Philadelphia (J.L.K.) Hackensack university Medical center Hackensack NJ (S.R.-Z.) the university of North Carolina at Chapel Hill Chapel Hill (K.A.K.) Bluebird Bio Cambridge MA (F.J.P. M.B. A.M. X.Z. J.L. D.K. J.-A.R. M.A. S.G.) Northwestern university Feinberg School of Medicine and Ann and Robert H. Lurie Children's Hospital - both in Chicago (A.A.T.) and the Cellular and Molecular Therapeutics Branch National Heart Lung and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases (NHLBI-NIDDK) National Institutes of Health Bethesda MD (J.F.T.).

Background:Sickle cell disease is characterized by the painful recurrence of vaso-occlusive *** therapy with the use of LentiGlobin for sickle cell disease(bb1111;lovotibeglogene autotemcel)consists of autologous transplantation of hematopoietic stem and progenitor cells transduced with the BB305 lentiviral vector encoding a modifiedβ-globin gene,which produces an antisickling hemoglobin,HbAT87Q.

关键词： Sick Clinical hematopoietic